Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ilse Krebs
Five-Year Outcomes of a Personalized Pro Re Nata Treatment Regimen With Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration
Acta Ophthalmologica
Medicine
Ophthalmology
Quality of the Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT
Investigative Ophthalmology and Visual Science
Molecular Neuroscience
Ophthalmology
Sensory Systems
Cellular
Related publications
Outcomes When Switching From a Pro Re Nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration
Ophthalmologica
Medicine
Ophthalmology
Sensory Systems
Vascular Endothelial Growth Factor Inhibitors in the Treatment of Neovascular Age-Related Macular Degeneration
Vestnik Oftalmologii
Medicine
Ophthalmology
Characterisation of Poor Visual Outcomes of Neovascular Age-Related Macular Degeneration Treated With Anti-Vascular Endothelial Growth Factor Agents
Ophthalmology
Ophthalmology
Vitreomacular Traction Affects Anti-Vascular Endothelial Growth Factor Treatment Outcomes for Exudative Age-Related Macular Degeneration
Retina
Medicine
Ophthalmology
An 8-Year Follow-Up of Anti-Vascular Endothelial Growth Factor Treatment With a Treat-And-Extend Modality for Neovascular Age-Related Macular Degeneration
Acta Ophthalmologica
Medicine
Ophthalmology
Simulating an Anti–Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis
Ophthalmology
Ophthalmology
One-Year Outcomes of 1 Dose Versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
Journal of Ophthalmology
Ophthalmology
Does Genetic Variation Influence Response to Treatment With Vascular Endothelial Growth Factor Inhibitors in Neovascular Age-Related Macular Degeneration?
Ophthalmic Epidemiology
Epidemiology
Ophthalmology
Intravitreal Injection of Ranibizumab Using A pro Re Nata Regimen for Age-Related Macular Degeneration and Vision-Related Quality of Life
Clinical Ophthalmology
Ophthalmology
